MedTrace Logo

Effect of Geranium Inhalation Aromatherapy on Pain and Blood Pressure in Cancer Patients Undergoing Chemotherapy

NCT07292844 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-12-18

No results posted yet for this study

Summary

This randomized controlled trial aims to examine the effect of geranium inhalation aromatherapy on pain and blood pressure among Indonesian cancer patients undergoing intravenous chemotherapy. A total of 90 participants under the age of 65 with normal BMI will be enrolled and randomly assigned to either an intervention group or a control group. The intervention group will receive geranium essential oil inhalation using three drops applied to cotton and inhaled for 15 minutes during chemotherapy sessions, while the control group will receive usual care without aromatherapy. Pain intensity will be measured using the Visual Analog Scale (VAS), and blood pressure will be recorded using a standard digital blood pressure monitor before and after the intervention. This study aims to evaluate whether geranium aromatherapy can be feasibly implemented as a complementary supportive therapy during chemotherapy. Study Started Date after January 18, 2017

Conditions

  • Cancer
  • Chemotherapy Induced Pain
  • Blood Pressure Changes in Cancer Patients
  • Chemotherapy Side Effects

Interventions

OTHER

Geranium Inhalation Aromatherapy

Participants received inhalation aromatherapy using geranium essential oil during their chemotherapy session. Three drops of geranium essential oil were placed on a piece of cotton positioned near the patient to allow continuous inhalation. The aromatherapy was administered for 15 minutes during chemotherapy and given twice per month. Pain intensity (VAS) and blood pressure were measured before and after each session. The control group received usual care without aromatherapy.

Sponsors & Collaborators

  • Universitas Muhammadiyah Surakarta

    lead OTHER

Principal Investigators

  • FIK UMS · Universitas Muhammadiyah Surakarta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2022-08-30
Completion
2022-09-30

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07292844 on ClinicalTrials.gov